Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
Avatar

Next Questions in Myeloma: Biology, Smoldering Myeloma, High-risk, MRD, and How to Salvage Therapy

By Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018) FEATURING Sundar Jagannath
October 24, 2018
0 Comments
Login to view comments. Click here to Login

Featured Video

18:52
Merck Oncology

A Treatment Option for Certain Patients With Locally Advanced or Met…

Feat. C. Hoimes

Featured Video

32:57
Merck Oncology

Case Studies Discussion on R/R cHL: Treatment Selection for Certain …

Feat. W. Donnellan, L. Leslie

Related Content

AUTOPLAY
16:57
SOHO Italy 1st School of Multiple Myeloma

Anti-CD38 in MM Daily Practice: How Can We Potentiate the Action of …

Feat. C. Cerchione
34:28
2022 Community Oncology Conference

Treatment Conundrums in Myeloma

Feat. S. Giralt
19:13
SOHO Italy 1st School of Multiple Myeloma

Daratumumab in MM Daily Practice: Is It Becoming the New Backbone?

Feat. C. Cerchione
06:50
ecancer

EHA 2021 Highlights on KRd for Lenalidomide-Refractory MM

Feat. C. Cerchione
15:24
SOHO 3rd Italian Conference

SOHO Italy 2021 on R/R MM Treatment in Europe

Feat. C. Cerchione
17:29
SOHO Italy 1st Clinical and Biological School of CAR-T

How to Integrate CAR-T in the Clinical Scenario of Multiple Myeloma

Feat. C. Cerchione
01:29
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on the Addition of Carfilzomib as a Thir…

Feat. C. Cerchione
26:05
SOHO Italy 1st School of Multiple Myeloma

Introducing Anti-CD38 in Daily Practice of MM: Updates on the GRIFFI…

Feat. C. Cerchione
15:57
SOHO 3rd Italian Conference

SOHO Italy 2021 on CAR T in MM: Preliminary Data and Perspectives

Feat. C. Cerchione
23:18
Oncology Data Advisor

Can Diet and Nutrition Impact Multiple Myeloma Outcomes?

Feat. U. Shah, R. Banerjee
17:47
SOHO 3rd Italian Conference

SOHO Italy 2021 on MM: State of the Art Therapy in Europe

Feat. C. Cerchione
22:16
SOHO Italy 1st School of Multiple Myeloma

Molecular Pathogenesis of MM: MGUS and SMM, Genomic Complexity of th…

Feat. N. Bolli
13:44
SOHO Italy 1st School of Multiple Myeloma

MRD Assessment Within the Bone Marrow of MM: Immunoglobulin Genes as…

Feat. C. Terragna
20:31
Ambuga Badari

Management of Multiple Myeloma in First Relapse

33:28
Cleveland Clinic Taussig Cancer Institute

Management of Relapsed/Refractory Multiple Myeloma

Feat. F. Anwer
04:26
ASCO 2022 Conference Coverage

2022 ASCO Annual Meeting "The Effects of AVM0703 Mobilization o…

Feat. J. Dalpez
15:12
Yale Cancer Center

ASH 2021: Cellular Therapies in Myeloma

Feat. N. Bar
30:24
University of Colorado Cancer Center

MRD in MM: How We Measure Disease Generally and What It Means for th…

Feat. B. Harry
10:50
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on the Efficacy and Safety of Cilta-Cel in R/R MM: …

Feat. A. Jakubowiak
26:18
Morie Gertz

Treatment of Relapsed Myeloma: Overview of Approved Drugs & Opti…